The plaintiff claims that the defendants failed to inform investors that sovaprevir did not interact well with other drugs commonly administered to treat hepatitis and/or HIV.
http://www.prlog.org/12237346-achillion-pharmaceuticals-inc-nasdaqachn-investor-lawsuit-alleges-misleading-statements.html
http://www.prlog.org/12237346-achillion-pharmaceuticals-inc-nasdaqachn-investor-lawsuit-alleges-misleading-statements.html
No comments:
Post a Comment